English Pharmaceutical Industries
Pharmaceutical manufacturer and contract manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer and contract manufacturer with multi-product production capabilities.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical manufacturer and contract manufacturer
- Address
- Lahore, Pakistan
- Website
- englishpharma.co ↗
- Phone
- +92 300 8435760
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Aculac | Lactulose | 3.35 g | Syrup | 120ml | 038031 | PKR 281.87 | PKR 2.35/mL | Near median |
| Amoclav | Amoxicillin + clavulanic acid | 1 g + 200 mg | Injection | 1's | 074243 | PKR 323.83 | PKR 323.83/vial/unit | Near median |
| Amoclav | Amoxicillin + clavulanic acid | 500 mg + 100 mg | Injection | 1's | 074244 | PKR 165.06 | PKR 165.06/vial/unit | 16% below median |
| Amsipol | Paracetamol + Caffeine | 500 mg + 65 mg | Tablet | 200's | 044683 | PKR 904.33 | PKR 4.52/tablet | Near median |
| Biotic-P | Benzathine penicillin G | 1.2 MIU | Injection | 1's | 074332 | PKR 43.52 | PKR 43.52/vial/unit | 68% below median |
| Biotic-P | Benzathine penicillin G | 0.6 MIU | IM injection | 1's | 074333 | PKR 29.67 | PKR 29.67/vial/unit | No comparator |
| Cefaz | Ceftazidime | 250 mg | Injection | vial | 040133 | PKR 158.01 | PKR 158.01/vial/unit | Near median |
| Cefaz | Ceftazidime | 500 mg | Injection | vial | 040134 | PKR 240.34 | PKR 240.34/vial/unit | Near median |
| Cefaz | Ceftazidime | 1 g | Injection | vial | 040135 | PKR 371.97 | PKR 371.97/vial/unit | 19% below median |
| Chroncef | Ceftriaxone | 250 mg | Injection | vial | 032124 | PKR 192.20 | PKR 192.20/vial/unit | Near median |
| Chroncef | Ceftriaxone | 500 mg | Injection | vial | 032125 | PKR 343.94 | PKR 343.94/vial/unit | 6% above median |
| Chroncef | Ceftriaxone | 1 g | Injection | vial | 032126 | PKR 606.95 | PKR 606.95/vial/unit | Near median |
| Chroncef | Ceftriaxone | 250 mg | Injection | vial | 032127 | PKR 192.20 | PKR 192.20/vial/unit | Near median |
| Chroncef | Ceftriaxone | 500 mg | Injection | vial | 032128 | PKR 343.94 | PKR 343.94/vial/unit | 6% above median |
| Chroncef | Ceftriaxone | 1 g | Injection | vial | 032129 | PKR 606.95 | PKR 606.95/vial/unit | Near median |
| Chroncef | Ceftriaxone | 2 g | IV injection | 1's | 074338 | PKR 890.03 | PKR 890.03/vial/unit | 6% above median |
| Ciliclox | Ampicillin + Cloxacillin | 250 mg + 250 mg | Injection | 10's | 074245 | PKR 434.61 | PKR 43.46/vial/unit | 7% above median |
| Ciliclox | Ampicillin + Cloxacillin | 125 mg + 125 mg | Injection | 10's | 074246 | PKR 302.34 | PKR 30.23/vial/unit | 35% below median |
| Cipronag | Ciprofloxacin | 250 mg | Tablet | 10's | 029014 | PKR 263.01 | PKR 26.30/tablet | Near median |
| Cipronag | Ciprofloxacin | 500 mg | Tablet | 10's | 029015 | PKR 526.03 | PKR 52.60/tablet | 23% above median |
| Cipronag | Ciprofloxacin | 200 mg | IV infusion | 50ml | 040136 | PKR 121.39 | PKR 2.43/mL | 13% above median |
| Cipronag | Ciprofloxacin | 200 mg | IV infusion | 100ml | 040136 | PKR 242.78 | PKR 2.43/mL | 13% above median |
| Colaite | Colistimethate sodium | 1 MIU | IV injection | 1's | 092529 | PKR 1,199.81 | PKR 1,199.81/vial/unit | Near median |
| Coliate | Colistimethate sodium | 2 MIU (≈68 mg colistin base activity) | Injection | 1's | 115682 | PKR 2,000.07 | PKR 2,000.07/vial/unit | 21% below median |
| Coliate | Colistimethate sodium | 68 mg | Injection | 1's | 115682 | PKR 2,000.07 | PKR 2,000.07/vial/unit | Near median |
| Coliate | Colistimethate sodium | 4.5 MIU (≈150 mg colistin base activity) | Injection | 1's | 116494 | PKR 4,501.60 | PKR 4,501.60/vial/unit | 13% above median |
| Coliate | Colistimethate sodium | 150 mg | Injection | 1's | 116494 | PKR 4,501.60 | PKR 4,501.60/vial/unit | Near median |
| E-Cip | Ciprofloxacin | 500 mg | Capsule | 10's | 059759 | PKR 434.99 | PKR 43.50/capsule | Near median |
| E-Cip | Ciprofloxacin | 250 mg | Capsule | 10's | 059760 | PKR 263.01 | PKR 26.30/capsule | Near median |
| E-Cip | Ciprofloxacin | 125 mg/5 mL | Suspension | 60ml | 067988 | PKR 182.09 | PKR 3.03/mL | 14% below median |
| E-Cip | Ciprofloxacin | 250 mg/5 mL | Suspension | 60ml | 067993 | PKR 323.71 | PKR 5.40/mL | 5% above median |
| E-Lev | Levofloxacin | 250 mg | Capsule | 10's | 059761 | PKR 404.64 | PKR 40.46/capsule | Near median |
| E-Lev | Levofloxacin | 500 mg | Capsule | 10's | 059762 | PKR 667.65 | PKR 66.77/capsule | Near median |
| Eaxiron | Cefotaxime | 0.25 g | Injection | Vial | 032130 | PKR 104.38 | PKR 104.38/vial/unit | 6% below median |
| Eaxiron | Cefotaxime | 0.5 g | Injection | Vial | 032131 | PKR 160.61 | PKR 160.61/vial/unit | 14% below median |
| Eaxiron | Cefotaxime | 1 g | Injection | Vial | 032132 | PKR 282.94 | PKR 282.94/vial/unit | Near median |
| Ekacin | Amikacin | 250 mg | Injection | 2mlx1's | 046406 | PKR 130.53 | PKR 65.27/mL | Near median |
| Ekacin | Amikacin | 500 mg | Injection | 2mlx1's | 046407 | PKR 238.07 | PKR 119.04/mL | Near median |
| Ekacin | Amikacin | 100 mg | Injection | 2mlx1's | 046408 | PKR 78.09 | PKR 39.05/mL | 9% below median |
| Ekacin | Amikacin | 50 mg | Injection | 1's | 047843 | PKR 47.61 | PKR 47.61/vial/unit | Near median |
| Eloglipten | Metformin | 500 mg | Tablet | 50's | 086288 | PKR 98.82 | PKR 1.98/tablet | 27% below median |
| Encogyl | Metronidazole (Benzoate) | 500 mg | Injection | Vial | 038370 | PKR 127.61 | PKR 127.61/vial/unit | No comparator |
| Enfal | Cefazolin | 250 mg | Injection | Vial | 040129 | PKR 78.67 | PKR 78.67/vial/unit | 5% above median |
| Enfal | Cefazolin | 500 mg | Injection | Vial | 040130 | PKR 118.00 | PKR 118.00/vial/unit | 6% below median |
| Enfal | Cefazolin | 1 g | Injection | Vial | 040131 | PKR 209.50 | PKR 209.50/vial/unit | Near median |
| Engmox | Moxifloxacin | 400 mg | Tablet | 5's | 036144 | PKR 961.00 | PKR 192.20/tablet | Near median |
| Engpan | Meropenem | 500 mg | Injection | 1's | 064555 | PKR 1,149.16 | PKR 1,149.16/vial/unit | 45% below median |
| Engsit | Ondansetron | 4 mg | Tablet | 10's | 126331 | PKR 1,065.68 | PKR 106.57/tablet | 15% above median |
| Engsit | Ondansetron | 8 mg | Tablet | 10's | 126332 | PKR 1,776.13 | PKR 177.61/tablet | 6% above median |
| Engsit | Ondansetron | 4 mg/5 mL | Syrup | 50ml | 126333 | PKR 1,032.63 | PKR 20.65/mL | 15% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.